Skip to content

I Have RP Posts

MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial

Source: Foundation Fighting Blindness Blog – Eye on the Cure – MeiraGTx Treats First Patient in XLRP Gene-Therapy Trial MeiraGTx, a gene-therapy company in London and New York City, has treated its first patient in a gene-therapy clinical trial for people with X-linked retinitis pigmentosa (XLRP) caused by mutations…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Second Sight Medical Products Inc. – Receive News & Ratings Daily

Source: Google News – Retinitis pigmentosa – Second Sight Medical Products Inc. – Receive News & Ratings Daily Second Sight Medical Products Inc. – Receive News & Ratings Daily  TrueBlueTribune Full coverage Source: Google News – Retinitis pigmentosa – Second Sight Medical Products Inc. – Receive News & Ratings…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest

Analysts Set Applied Genetic Technologies Corporation (AGTC) Price Target at $14.63

Source: Google News – Retinitis pigmentosa – Analysts Set Applied Genetic Technologies Corporation (AGTC) Price Target at .63 Analysts Set Applied Genetic Technologies Corporation (AGTC) Price Target at $14.63  TrueBlueTribune EPS for Applied Genetic Technologies Corp (AGTC) Expected At $0.11  WeeklyHub Full coverage Source: Google News – Retinitis pigmentosa –…

Email this to someoneTweet about this on TwitterShare on FacebookShare on Google+Pin on Pinterest